Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “AstraZeneca”
- A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCActive Not Recruiting
Sponsor: AstraZeneca
HER2-mutant Non-Small Cell Lung Cancer
China
- A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)Active Not Recruiting
Sponsor: AstraZeneca
Locally Advanced Cervical Cancer
Russia
Sponsor: AstraZeneca
Atypical Hemolytic Uremic Syndrome
Egypt
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active Not Recruiting
Sponsor: AstraZeneca
ER+ HER2- Advanced Breast Cancer
United States, Spain, United Kingdom
Sponsor: AstraZeneca
Healthy Participants
United States
Sponsor: AstraZeneca
Staphylococcus Aureus Bloodstream Infection
Japan
- A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Active Not Recruiting
Sponsor: AstraZeneca
Neurofibromatosis 1 · Neurofibroma Plexiform
China
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, Brazil, Canada, Hong Kong, Japan +5 more
- A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerRecruiting
Sponsor: AstraZeneca
Metastatic Colorectal Cancer
United States, Australia, Canada, China, France +7 more
- Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCActive Not Recruiting
Sponsor: ETOP IBCSG Partners Foundation
Non-small Cell Lung Cancer · Stage IV · Oligometastasis
Italy, Netherlands, Spain, Switzerland
Sponsor: AstraZeneca
Gastroesophageal Adenocarcinoma
United States, Canada, China, Georgia, Italy +6 more
Sponsor: AstraZeneca
Relapsed/Refractory Multiple Myeloma
United States
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive Not Recruiting
Sponsor: AstraZeneca
Breast Cancer
China
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active Not Recruiting
Sponsor: AstraZeneca
Locally Advanced (Inoperable) or Metastatic Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +18 more
Sponsor: AstraZeneca
Asthma
United States, Argentina, Brazil, Canada, China +17 more
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursActive Not Recruiting
Sponsor: AstraZeneca
Solid Tumors
Canada, United Kingdom
Sponsor: AstraZeneca
Breast Cancer
Bulgaria, Slovenia
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Canada, China +12 more
Sponsor: AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
China
Sponsor: AstraZeneca
Respiratory (Chronic Obstructive Pulmonary Disease)
Turkey (Türkiye)
- Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentActive Not Recruiting
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Australia, Austria, Brazil, Canada +19 more
Sponsor: AstraZeneca
Newly Diagnosed Multiple Myeloma
United States, Australia, Brazil, Canada, Denmark +10 more
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Neoplasms
United States, Argentina, Australia, Canada, Colombia +16 more
Sponsor: AstraZeneca
Chronic Lymphocytic Leukaemia · Moderate to Severe Cardiac Impairment
United States, Czechia, Italy, Poland, Spain +1 more
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Head and Neck Squamous Cell Carcinoma · Metastatic Squamous Cell Carcinoma
Canada